Thursday, 29 Jun 2017

Biologic/Novel Rx

Datesort ascending Type Title Save
13 Jun 2017 News Supreme Court Decision Favors Earlier Biosimilar Adoption
07 Jun 2017 News Upadacitinib Effective in Rheumatoid Arthritis
05 Jun 2017 News Biosimilar Reports – May 2017
25 May 2017 Social RT @RWCSmtg: NOR-SWITCH trial suggests Remicade Can Be Substituted for Less Expensive Biosimilar CT-P13 https://t.co/oTpLD9Qymf #psoriasis…
24 May 2017 News Anti-IL-5 Success in Eosinophilic Granulomatosis with Polyangiitis
23 May 2017 Social Kevzara-the 2nd IL-6 inhibitor approved for use in RA; priced at $39K, 30% below competition https://t.co/mzIOOhEnMe https://t.co/2U3J2sskum
23 May 2017 Social FDA approves Actemra as1st approved drug to treat Giant Cell Arteritis. See RheumNow report. https://t.co/73UieZpbn1 https://t.co/HjUzi0H6OL
23 May 2017 News Actemra - First FDA Approved Drug for Giant Cell Arteritis
22 May 2017 Social @naseema22537544 @DrSimply The new updated PI says its to be given with a tapering course of steroids. https://t.co/SCaiX1FDQx
18 May 2017 Social RT @DrPetryna: @RheumNow could ustekinumab potentially be used in treatment of refractory GCA? Evidence suggests it might https://t.co/Ydr0…
15 May 2017 Social In #Crohns disease Tofacitinib fails to maintain remission in randomized W/D, results of 2 Placebo RCT. https://t.co/9KXQxdq9kw
12 May 2017 Social Uptacitinib (Abbvie Jak 1 inhibitor) shows efficacy in Crohns dz (CELESTE RCTl) w/ remission rates at 6 &24 mg bid https://t.co/ssZT2D6nWk
10 May 2017 Social Responses to Orencia may be dependent on baseline memory B cells (CD38+ CD27+) https://t.co/zro040Y54W
07 May 2017 Social FDA has accepted Sanofi/Regenerons resubmitted BLA for Sarilumab (IL-6 inhib) for RA w/ PFUFA action date 5/22/17 https://t.co/F9txx9QwLz
05 May 2017 Social Japan Study shows 8mg IV Actemra can be escalated to q3 wks IV or reduced to q5 wks IV according to q4wk response https://t.co/rLn6aJowry
04 May 2017 News Tofacitinib Effective in Ulcerative Colitis
04 May 2017 Social Pfizer submitted tofacitinib NDA to FDA for psoriatic arthritis. FDA prev denied the NDA for psoriasis w/ CR letter. https://t.co/bDmnc8QF3c
04 May 2017 Social Fostamatinib (Tavalisse) Syk inhib failed in RA, has been studied in ITP, new NDA for ITP submitted to FDA by Rigel. https://t.co/Nwull2hiB3
01 May 2017 Social OPT 1&2 RCT show Tofacitinib to improve nail psoriasis: NAPSI75 scores PBO 6.8%, Tofa 5mg 16.9%, 10 mg 28.1% bid https://t.co/YCtVbkF5Cf
29 Apr 2017 Social RT @NYTHealth: You asked: What is it about so many medications that causes dryness in the mouth? Here's a short explanation. https://t.co/B…